Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2004 (Q1 2004)
Comparison Period: Three months ended March 31, 2003
Alcon operates globally through two segments: Alcon United States and Alcon International. The company markets products in three categories: pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | Q1 2004 | Q1 2003 |
|---|---|---|
| Sales (Revenue) | $963.6 | $807.1 |
| Gross Profit | $673.8 | $553.8 |
| Gross Margin | 69.9% | 68.6% |
| Operating Income | $276.6 | $194.4 |
| Net Earnings | $191.0 | $130.2 |
| Diluted EPS | $0.61 | $0.42 |
| Cash from Operations | $190.6 | $166.6 |
| Cash & Equivalents (End of Period) | $923.2 | $919.0 |
| Total Debt | $1,290.4 | $1,410.3 |
| Net Debt | $367.2 | $324.3 |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 19.4% year-over-year. Excluding favorable foreign exchange rates (6.4% impact), constant currency sales grew 13.0%.
- Profitability: Net earnings rose 46.7% to $191.0 million, driven by a 42.3% increase in operating income. Gross margin expanded to 69.9% due to product mix shifts and lower manufacturing costs.
- Segment Performance:
- Pharmaceuticals: Sales up 25.3% (20.5% constant currency), led by Vigamox, Travatan, Azopt, and Ciprodex.
- Surgical: Sales up 17.8% (9.9% constant currency), driven by AcrySof Natural lenses and the Infiniti vision system. Refractive product sales declined 14.6%.
- Consumer Eye Care: Sales up 10.2% (4.4% constant currency), with strong growth in artificial tears.
- Geographic: U.S. sales grew 13.6%; International sales grew 25.8% (12.3% constant currency), significantly aided by the strengthening Euro and Yen.
- Capital Allocation: The company spent $162.0 million to repurchase 2.6 million treasury shares to satisfy future stock option exercises.
Guidance, Outlook, and Risks
- Tax Outlook: Management anticipates resolving significant tax audit issues and completing a study for research and experimentation tax credits as early as Q2 2004. This could result in a current tax benefit of up to $45 million, though realization is not assured.
- Dividend: The company expects to declare a dividend based on 2003 operations of approximately $0.55 per share (CHF 0.72), totaling an estimated $169 million, payable in May 2004 pending shareholder approval.
- Liquidity: The company maintains $2.9 billion in credit and commercial paper facilities. Net debt increased to $367.2 million due to share repurchases, but management believes cash flows and credit facilities are sufficient for future needs.
- Risks:
- Currency: Significant exposure to foreign exchange fluctuations; a 10% depreciation in non-U.S. dollar currencies could adversely affect sales contracts.
- Interest Rates: Majority of debt is short-term floating rate; a 1% increase in rates would decrease pre-tax earnings by $1.7 million.
- Regulatory/Competition: Risks include changes in reimbursement procedures, patent expirations (e.g., Ciloxan in June 2004), and product recalls.
Investor Verification Checklist
- Tax Benefit Realization: Verify if the anticipated $45 million tax benefit is recorded in Q2 2004 as projected.
- Share Repurchase Program: Confirm the status of the newly authorized 4 million share repurchase program approved in February 2004.
- Product Lifecycle: Monitor sales trends for Ciloxan as its patent expires in June 2004 and the impact of Vigamox adoption.
- Foreign Exchange Sensitivity: Assess the impact of currency fluctuations on future earnings, given the 6.4% positive impact in Q1 2004.
- Dividend Approval: Confirm shareholder approval of the proposed dividend at the April 27, 2004 meeting.